Skip to main content

PTC Hosts Interactive Panel Discussion on Gene Therapy Policy in Europe

June 22, 2021

  1. PTC Hosts Interactive Panel Discussion on Gene Therapy Policy in Europe

    PTC Therapeutics teamed up with the Alliance for Regenerative Medicine (ARM) to host an interactive panel discussion on cell and gene therapies for rare diseases. This event explored how policy leaders can work together to advance access to cell and gene therapy in Europe. Watch the video! The growing number of advanced therapy medicinal products…

  2. PTC Receives Prestigious Gallup Honor

    PTC is excited to announce our company has been named a winner of the 2021 ”Don Clifton Strengths-Based Culture Award” from Gallup. The award recognizes organizations with strong workplace cultures that get the best out of their employees. This honor is named for Don Clifton, an educational psychology professor at the University of Nebraska-Lincoln and…

  3. Gene Therapy: A New Paradigm in Rare Diseases

    This article has been extracted from the special “Grand Angle dossier” on rare diseases, produced by CommEdition, published in Le Monde on 27 February 2021. It has been translated to English (below). You can also download the original French publication from this webpage. The emergence of a new generation of treatments in biotechnology has aroused…

  4. Why MLK Day Matters at Work

    On Monday January 18, 2021, PTC – along with many other inclusive organizations – will celebrate the legacy of the honorable Dr. Martin Luther King, Jr. This is a day when we celebrate how the contributions of Dr. King evolved the growth of minority opportunities within organizations and communities regardless of race, gender or religion.…

  5. PTC Wins 2020 Pharma Award for Disease Awareness

    Congratulations to PTC’s Italian team for winning the Reuters Events Pharma Awards Europe 2020 award in the category of Most Valuable Awareness Initiative for Well-Child Visits for Life. This public awareness campaign promoted earlier diagnosis for children with Duchenne muscular dystrophy, a rare and debilitating disease. This campaign was centered around a hero video that…

  6. Our CEO Has Big Plans

    PTC founder and Chief Executive Officer, Stuart Peltz, Ph.D., was recently the subject of a MassBio profile. When asked about the future of PTC, he had this to say: PTC has been growing rapidly over the last two years and we will continue to grow and expand in the upcoming year. We plan to launch…

  7. Expanding Areas of Therapeutic Focus – Phenylketonuria (PKU)

    PTC has successfully completed acquisition of Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic rare diseases, including phenylketonuria (PKU) and other rare diseases associated with defects in the tetrahydrobiopterin (BH4) biochemical pathways diagnosed at birth. “This acquisition adds a well-established late-stage PKU clinical…

  8. Expanding Gene Therapy Development in a State-of-the-Art Biologics Facility

    A long-term lease agreement with Bristol-Myers Squibb Company provides us more than 185,000 square feet of space, including an existing state-of-the-art biologics production facility and supporting research and operations buildings on the BMS Hopewell, New Jersey campus. We plan to further develop the biologics facility to support gene therapy production and foster innovation and employment…